EHR

Health Systems Brace for Significant 2025 Cost Surge, Shift to GPOs and Outsourcing for Supply Chain Solutions, Black Book Survey Finds

Hospitals are not just outsourcing procurement but also forming deeper strategic partnerships with GPOs. These partnerships go beyond price negotiation…

1 year ago

Company Statement on FDA Advisory Committee Meeting  

MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug…

1 year ago

US Digital Health Market Insights & Forecast 2024-2028, with Profiles of Leading Players Apple, McKesson, Alphabet, Cisco Systems, Cerner and Allscripts Healthcare Solutions – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "US Digital Health Market (by Technology & Component): Insights & Forecast (2024-2028)" report has been added to ResearchAndMarkets.com's…

1 year ago

MIE2024 Conference article shows material data quality improvement and time savings in clinical trial data capture with nCartes

FREMONT, Calif., Sept. 12, 2024 /PRNewswire/ -- The 34th Medical Informatics Europe Conference was held in Athens, Greece August 25-29, 2024.…

1 year ago

CERECORE WINS CLEARLYRATED’S 2024 BEST OF STAFFING CLIENT AND TALENT 5 YEAR DIAMOND AWARDS FOR SERVICE EXCELLENCE

Diamond award winners have won the Best of Staffing award for at least 5 years in a row, consistently earning…

1 year ago

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract…

1 year ago

Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference

LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical…

1 year ago

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a…

1 year ago

Treace Highlights New Product Innovations and Updated Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2024

PONTE VEDRA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical…

1 year ago